In today’s recent session, 0.63 million shares of the Processa Pharmaceuticals Inc (NASDAQ:PCSA) have been traded, and its beta is 1.32. Most recently the company’s share price was $0.25, and it changed around $0.01 or 6.17% from the last close, which brings the market valuation of the company to $3.03M. PCSA at last check was trading at a discount to its 52-week high of $3.10, offering almost -1140.0% off that amount. The share price’s 52-week low was $0.15, which indicates that the recent value has risen by an impressive 40.0% since then. We note from Processa Pharmaceuticals Inc’s average daily trading volume that its 10-day average is 2.12 million shares, with the 3-month average coming to 2.68 million.
Processa Pharmaceuticals Inc stock received a consensus recommendation rating of Hold, based on a mean score of 2.00. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 1 rate it as Overweight. Among the rest, 1 recommended PCSA as a Hold, whereas 0 deemed it a Buy, and 0 rated it as Underweight. Processa Pharmaceuticals Inc is expected to report earnings per share of -0.65 for the current quarter.
Processa Pharmaceuticals Inc (NASDAQ:PCSA) trade information
Instantly PCSA has been showing a green trend so far today with a performance of 6.17% on intraday trading today. The performance over the last five days has remained in the green territory. The rise to weekly highs of 0.3190 on recent trading dayincreased the stock’s daily price by 21.63%. The company’s shares are currently down -71.20% year-to-date, but still up 5.21% over the last five days. On the other hand, Processa Pharmaceuticals Inc (NASDAQ:PCSA) is 7.29% up in the 30-day period. We can see from the shorts that 2.01 million shares have been sold at a short interest cover period of 0.39 day(s).
The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 97.22% from its current value. Analyst projections state that PCSA is forecast to be at a low of $9 and a high of $9.
Forecasts for the next quarter put sales growth at 0.00%.
Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 22.65%. Processa Pharmaceuticals Inc earnings are expected to increase by 77.00% in 2025, but the outlook is positive 42.13% per year for the next five years.
PCSA Dividends
Processa Pharmaceuticals Inc’s next quarterly earnings report is expected to be released on 2025-May-08.
Processa Pharmaceuticals Inc (NASDAQ:PCSA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 11.12% of Processa Pharmaceuticals Inc shares, and 1.88% of them are in the hands of institutional investors. The stock currently has a share float of 2.11%.
Fidelity Concord Street Trust-Fidelity Extended Market Index Fund and VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund were the top two Mutual Funds as of Mar 31, 2025 . The former held 29.24 shares worth $7506.0, making up 0.25% of all outstanding shares. On the other hand, VANGUARD INDEX FUNDS-Vanguard Extended Market Index Fund held roughly 24.43 shares worth around $6271.0, which represents about 0.21% of the total shares outstanding.
